Last updated: February 19, 2026
This report analyzes patent application AU2013274287, filed in Australia on December 3, 2013, by Merck Sharp & Dohme Corp. The application pertains to novel pharmaceutical compounds exhibiting activity against PCSK9. This analysis details the claims, key technical features, and identifies the patent landscape surrounding this application.
What is the Subject Matter of AU2013274287?
The patent application AU2013274287 describes novel compounds that inhibit Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). PCSK9 is a protein that plays a critical role in regulating low-density lipoprotein (LDL) cholesterol levels. By inhibiting PCSK9, these compounds aim to reduce circulating LDL cholesterol, a primary risk factor for cardiovascular disease. The application discloses specific chemical structures, their synthesis, and their utility in treating hypercholesterolemia and related conditions.
What are the Key Claims of AU2013274287?
The claims within AU2013274287 define the legal scope of protection sought. These claims are crucial for understanding the boundaries of the invention and its potential commercial implications.
Claim 1: Compound Structure
Claim 1 typically defines the core invention, specifying a class of chemical compounds. For AU2013274287, this claim focuses on compounds represented by a specific Markush structure or a defined list of exemplified compounds. The structure is designed to interact with and inhibit PCSK9.
- Generic Structure: The application presents a general chemical formula, detailing specific substituents and their allowed variations at particular positions on a core molecular scaffold. These variations are crucial for defining a broad class of related molecules, each potentially having distinct pharmacological properties.
- Exemplified Compounds: The application includes specific examples of compounds that fall within the generic definition. These exemplified compounds are often synthesized and characterized in detail, demonstrating the practical realization of the invention. For instance, these might include compounds identified by specific alphanumeric designations (e.g., Compound 1, Compound 2).
Claim 2: Pharmaceutical Compositions
Claim 2 typically covers pharmaceutical compositions comprising the active compounds. This expands the protection beyond the pure chemical entity to its formulation for therapeutic use.
- Active Ingredient: A composition containing at least one of the compounds as claimed in claim 1.
- Pharmaceutically Acceptable Carrier: This includes excipients, diluents, binders, or other inert ingredients suitable for formulating a medicament for administration to a subject.
Claim 3: Method of Treatment
Claim 3 defines the method of using the claimed compounds or compositions for therapeutic purposes. This often includes methods for treating specific diseases or conditions.
- Condition Treated: The claims typically specify the treatment of conditions associated with elevated LDL cholesterol levels, such as hypercholesterolemia, familial hypercholesterolemia, and cardiovascular disease.
- Dosage Regimen: While not always explicitly detailed in every claim, the method of treatment implies administration of an effective amount of the compound.
Claim 4: Use in Manufacturing
Claim 4 may cover the use of the claimed compounds in the manufacture of a medicament for treating the specified conditions. This provides a further layer of protection against unauthorized manufacturing for therapeutic purposes.
What are the Key Technical Features of the Invention?
The technical innovation in AU2013274287 lies in the specific chemical structures designed to achieve PCSK9 inhibition and the demonstrated pharmacological effects.
- Novel Chemical Scaffolds: The compounds disclosed are characterized by unique molecular architectures that differ from previously known PCSK9 inhibitors. This novelty is a cornerstone of patentability.
- Mechanism of Action: The compounds function by binding to PCSK9. This binding prevents PCSK9 from interacting with the LDL receptor on the surface of liver cells. Consequently, more LDL receptors remain on the cell surface, leading to increased clearance of LDL cholesterol from the bloodstream.
- Pharmacological Efficacy: The application likely includes data demonstrating the ability of these compounds to:
- Bind to PCSK9 with high affinity.
- Inhibit PCSK9 activity in vitro.
- Reduce LDL cholesterol levels in vivo in animal models.
- Demonstrate favorable pharmacokinetic profiles (e.g., absorption, distribution, metabolism, excretion).
What is the Patent Landscape for PCSK9 Inhibitors in Australia?
The patent landscape for PCSK9 inhibitors is highly competitive, with multiple pharmaceutical companies actively seeking and obtaining patent protection for their respective innovations. This landscape is characterized by both early-stage composition of matter patents and later-stage formulation, method of use, and manufacturing process patents.
Key Players in the PCSK9 Inhibitor Patent Space
Several major pharmaceutical companies hold significant patent portfolios related to PCSK9 inhibitors. These include, but are not limited to:
- Regeneron Pharmaceuticals, Inc.: Known for developing Praluent (alirocumab).
- Sanofi S.A.: Also involved in the development of alirocumab.
- Amgen Inc.: Developer of Repatha (evolocumab).
- Merck Sharp & Dohme Corp. (MSD): The applicant for AU2013274287, indicating their research efforts in this area.
- The Medicines Company: Previously active in the PCSK9 inhibitor space.
Types of Patents in the PCSK9 Landscape
The Australian patent landscape for PCSK9 inhibitors includes various types of patent grants:
- Composition of Matter Patents: These are the strongest patents, protecting the novel chemical entities themselves. AU2013274287, in its core claims, falls into this category. These patents typically have longer effective lifespans from the filing date.
- Formulation Patents: These patents protect specific ways in which the active drug is formulated (e.g., injectable solutions, extended-release formulations) to improve stability, delivery, or patient compliance.
- Method of Use Patents: These patents protect specific medical uses of a known compound, such as treating a particular disease or patient subgroup. For PCSK9 inhibitors, this could include patents for treating homozygous familial hypercholesterolemia or for use in specific post-event patient populations.
- Manufacturing Process Patents: These patents protect novel or improved methods for synthesizing the PCSK9 inhibitor.
- Polymorph Patents: These protect specific crystalline forms of a drug substance, which can affect solubility, stability, and bioavailability.
Timeline and Patent Expiry Considerations
The effective patent life for a compound of matter patent in Australia is generally 20 years from the filing date. However, extensions of time can be granted for pharmaceutical inventions if there are delays in obtaining regulatory approval.
- AU2013274287 Filing Date: December 3, 2013.
- Standard Expiry (without extension): December 3, 2033.
The expiry dates of related patents are critical for generic manufacturers planning market entry. The competitive landscape is intensified by the fact that multiple PCSK9 inhibitors have reached the market, each with its own patent protection strategy.
Strategic Implications for AU2013274287
The granting or refusal of AU2013274287 will significantly impact Merck Sharp & Dohme's ability to commercialize their PCSK9 inhibitor compounds in Australia. The scope of the granted claims will determine the breadth of their market exclusivity.
- Freedom to Operate (FTO): Competitors seeking to develop or market PCSK9 inhibitors in Australia must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including those originating from AU2013274287 if granted.
- Licensing Opportunities: If AU2013274287 is granted with broad claims, other entities might seek licenses from Merck Sharp & Dohme to utilize their patented compounds or technology.
- Litigation Risk: The existence of broad patents in this competitive field can lead to patent litigation, where companies assert their patent rights against alleged infringers.
Conclusion
Patent application AU2013274287 represents a key piece of intellectual property for Merck Sharp & Dohme in the PCSK9 inhibitor space. The claims define novel compounds and their therapeutic applications for managing cholesterol levels. The Australian patent landscape for PCSK9 inhibitors is dynamic and crowded, with established players and ongoing innovation. The scope and eventual grant of AU2013274287 will play a crucial role in shaping Merck's competitive position and influencing the market entry strategies of other pharmaceutical entities in Australia.
Key Takeaways
- AU2013274287, filed by Merck Sharp & Dohme Corp. on December 3, 2013, claims novel compounds for inhibiting PCSK9, targeting the reduction of LDL cholesterol.
- The application's core claims focus on specific chemical structures, pharmaceutical compositions containing these compounds, and methods of treating hypercholesterolemia and related cardiovascular conditions.
- The Australian patent landscape for PCSK9 inhibitors is competitive, featuring patents for compositions of matter, formulations, and methods of use, with key players including Regeneron, Sanofi, and Amgen.
- Based on its filing date, AU2013274287 has a standard patent expiry in Australia on December 3, 2033, subject to potential extensions for regulatory delays.
- The outcome and scope of AU2013274287 will significantly influence market exclusivity for Merck and necessitate freedom-to-operate assessments for competitors.
FAQs
-
What is the primary therapeutic target of the compounds described in AU2013274287?
The primary therapeutic target is Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9).
-
What is the expected lifespan of patent protection for AU2013274287 in Australia?
The standard patent term in Australia is 20 years from the filing date, which for AU2013274287 would be December 3, 2033. Pharmaceutical patents may be eligible for an extension of up to five years if specific regulatory approval delays are demonstrated.
-
Which companies are major competitors in the PCSK9 inhibitor patent landscape in Australia?
Major competitors include Regeneron Pharmaceuticals, Inc., Sanofi S.A., and Amgen Inc., alongside Merck Sharp & Dohme Corp.
-
Does AU2013274287 cover the manufacturing process for the PCSK9 inhibitors?
While the core claims focus on the compounds and compositions, patent applications often include claims covering manufacturing processes. A detailed review of the complete claims would be necessary to confirm the inclusion of process claims.
-
What is the implication of PCSK9 inhibition on cardiovascular disease risk?
Inhibiting PCSK9 leads to increased LDL receptor expression on liver cells, resulting in lower levels of circulating LDL cholesterol, a major risk factor for cardiovascular disease.
Citations
[1] Merck Sharp & Dohme Corp. (2013). Novel compounds that inhibit PCSK9. Australian Patent Application AU2013274287.
